Literature DB >> 9814464

Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects.

R Kuromaru1, H Kohno, N Ueyama, H M Hassan, S Honda, T Hara.   

Abstract

GH has many effects on metabolism in addition to promoting growth. We studied changes in body composition and lipid profiles during and after GH treatment in 94 children with GH deficiency. Sixty-two subjects (46 boys and 16 girls) were evaluated at the beginning and during 36 months of GH treatment. The other 32 (21 boys and 11 girls) who had already been treated with GH were examined after the discontinuation of GH for a 6-month period. The height SD scores at the beginning and the discontinuation of GH treatment were -2.81 and -1.34 in boys and -3.14 and -1.38 in girls, respectively. The percent body fat (BF) significantly decreased from 16.5% to 11.7% in boys and from 16.7% to 11.6% in girls during the first 6 months of GH treatment (P < 0.01). BF subsequently remained constant in boys, but started to increase in girls from the 18th month of treatment. Lean body mass (kilograms) increased linearly throughout the treatment in both sexes (P < 0.01). Mean total cholesterol (TC) values decreased as a result of marked declines in low density lipoprotein cholesterol in both sexes, although statistical significance was detected only in boys (P < 0.01). High density lipoprotein cholesterol (HDLC) and apolipoprotein AI (Apo-AI) rapidly increased only in boys (P < 0.01). Triglyceride, Apo-AII, Apo-B, Apo-CII, Apo-CIII, Apo-E, and lipoprotein(a) showed no significant changes compared with baseline levels. Mean TC/HDLC and Apo-B/Apo-AI ratios decreased during treatment in both sexes, but the difference from baseline was significant only in boys (P < 0.01). After discontinuation of GH treatment, BF increased, and lean body mass decreased in boys (P < 0.01), whereas these variables did not change in girls. TC and low density lipoprotein cholesterol increased in boys within 6 months of discontinuing GH (P < 0.05). Other lipoproteins did not change in either sex, except for lipoprotein(a), which decreased significantly 6 months after the cessation of GH treatment in boys (P < 0.01). The mean TC/HDLC and Apo-B/Apo-AI ratios increased in boys slightly, but insignificantly. We concluded that GH treatment has beneficial effects on body composition and lipid profiles in both boys and girls with GH deficiency, although there are considerable gender differences. These beneficial effects of GH were reversed after the discontinuation of GH treatment, suggesting an important role of GH for GH-deficient children in the maintenance of normal metabolism even after the completion of linear growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814464     DOI: 10.1210/jcem.83.11.5261

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Feed intake and protein skeletal muscle in growing mice treated with growth hormone: time course effects.

Authors:  M E López-Oliva; A Agis-Torres; M T Unzaga; E Muñoz-Martínez
Journal:  J Physiol Biochem       Date:  2000-03       Impact factor: 4.158

2.  Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults.

Authors:  Johannes D Veldhuis; Ferdinand Roelfsema; Daniel M Keenan; Steven Pincus
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

3.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

4.  Effects of Growth Hormone Treatment on Lipid Profiles.

Authors:  Toshihide Kubo; Mahoko Furujo; Kyohei Takahashi; Yuki Hyodo; Hiroki Tsuchiya; Mariko Hattori; Shoko Fujinaga; Kenji Urayama
Journal:  Indian J Pediatr       Date:  2017-11-11       Impact factor: 1.967

5.  Inherent sex-dependent regulation of human hepatic CYP3A5.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Permanent uncoupling of male-specific CYP2C11 transcription/translation by perinatal glutamate.

Authors:  Sarmistha Banerjee; Rajat Kumar Das; Kelly A Giffear; Bernard H Shapiro
Journal:  Toxicol Appl Pharmacol       Date:  2015-02-16       Impact factor: 4.219

7.  Irreversible perinatal imprinting of adult expression of the principal sex-dependent drug-metabolizing enzyme CYP2C11.

Authors:  Rajat Kumar Das; Sarmistha Banerjee; Bernard H Shapiro
Journal:  FASEB J       Date:  2014-06-18       Impact factor: 5.191

8.  C-reactive protein levels in subjects with Prader-Willi syndrome and obesity.

Authors:  Merlin G Butler; Douglas C Bittel; Nataliya Kibiryeva; Uttam Garg
Journal:  Genet Med       Date:  2006-04       Impact factor: 8.822

9.  Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children.

Authors:  Björn Andersson; Gunnel Hellgren; Andreas F M Nierop; Ze'ev Hochberg; Kerstin Albertsson-Wikland
Journal:  Proteome Sci       Date:  2009-11-02       Impact factor: 2.480

10.  Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency.

Authors:  Hitoshi Kohno; Toshiaki Tanaka; Kenji Fujieda; Kazuo Chihara; Yoshiki Seino; Minoru Irie; Kazue Takano
Journal:  Clin Pediatr Endocrinol       Date:  2012-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.